Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer

Lung Cancer

Volumn 83, Issue 1, 2014, Pages 90-96

  Ohgino, Keiko ^a   Soejima, Kenzo ^a   Yasuda, Hiroyuki ^a   Hayashi, Yuichiro ^a   Hamamoto, Junko ^a   Naoki, Katsuhiko ^a   Arai, Daisuke ^a   Ishioka, Kota ^a   Sato, Takashi ^a   Terai, Hideki ^a   Ikemura, Shinnosuke ^a   Yoda, Satoshi ^a   Tani, Tetsuo ^a   Kuroda, Aoi ^a   Betsuyaku, Tomoko ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; CDNA microarray; Fibroblast growth factor 9; Immunohistochemistry; Non small cell lung cancer; Prognosis; Squamous cell carcinoma

Indexed keywords

COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR 9;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL EVALUATION; DISEASE SEVERITY; DNA MICROARRAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; CDNA MICROARRAY; FIBROBLAST GROWTH FACTOR 9; IMMUNOHISTOCHEMISTRY; NON-SMALL CELL LUNG CANCER; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FIBROBLAST GROWTH FACTOR 9; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PROGNOSIS; PULMONARY SURGICAL PROCEDURES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891744568     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.10.016     Document Type: Article

References (36)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012, 62:10-29.
2. Liu L., Zhao E., Li C., Huang L., Xiao L., Cheng L., et al. TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer. Cancer Epidemiology 2013, 37:71-78.
3. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biology 2001, 2. REVIEWS3005.
4. Grose R., Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine & Growth Factor Reviews 2005, 16:179-186.
5. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nature Reviews. Cancer 2010, 10:116-129.
6. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug Discovery 2009, 8:235-253.
7. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine & Growth Factor Reviews 2005, 16:139-149.
8. Marek L., Ware K.E., Fritzsche A., Hercule P., Helton W.R., Smith J.E., et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Molecular Pharmacology 2009, 75:196-207.
9. Behrens C., Lin H.Y., Lee J.J., Raso M.G., Hong W.K., Wistuba I.I., et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:6014-6022.
10. Leushacke M., Sporle R., Bernemann C., Brouwer-Lehmitz A., Fritzmann J., Theis M., et al. An RNA interference phenotypic screen identifies a role for FGF signals in colon cancer progression. PloS ONE 2011, 6:e23381.
11. Teishima J., Shoji K., Hayashi T., Miyamoto K., Ohara S., Matsubara A. Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence. Prostate Cancer and Prostatic Diseases 2012, 15:8-14.
12. Yin Y., Wang F., Ornitz D.M. Mesothelial- and epithelial-derived FGF9 have distinct functions in the regulation of lung development. Development 2011, 138:3169-3177.
13. Wang C.K., Chang H., Chen P.H., Chang J.T., Kuo Y.C., Ko J.L., et al. Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas. International Journal of Cancer. Journal International DU Cancer 2009, 125:807-815.
14. Wojtalla A., Fischer B., Kotelevets N., Mauri F.A., Sobek J., Rehrauer H., et al. Targeting the phosphoinositide 3-kinase p110-alpha isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2013, 19:96-105.
15. Lin W.M., Baker A.C., Beroukhim R., Winckler W., Feng W., Marmion J.M., et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research 2008, 68:664-673.
16. Dutt A., Salvesen H.B., Chen T.H., Ramos A.H., Onofrio R.C., Hatton C., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:8713-8717.
17. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genetics 1999, 23:18-20.
18. Courjal F., Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Research 1997, 57:4368-4377.
19. Gorringe K.L., Jacobs S., Thompson E.R., Sridhar A., Qiu W., Choong D.Y., et al. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2007, 13:4731-4739.
20. Weiss J., Sos M.L., Seidel D., Peifer M., Zander T., Heuckmann J.M., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2010, 2:62ra93.
21. Dutt A., Ramos A.H., Hammerman P.S., Mermel C., Cho J., Sharifnia T., et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PloS ONE 2011, 6:e20351.
22. Kunii K., Davis L., Gorenstein J., Hatch H., Yashiro M., Di Bacco A., et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Research 2008, 68:2340-2348.
23. Xiao S., Nalabolu S.R., Aster J.C., Ma J., Abruzzo L., Jaffe E.S., et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nature Genetics 1998, 18:84-87.
24. Roumiantsev S., Krause D.S., Neumann C.A., Dimitri C.A., Asiedu F., Cross N.C., et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004, 5:287-298.
25. Yagasaki F., Wakao D., Yokoyama Y., Uchida Y., Murohashi I., Kayano H., et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Research 2001, 61:8371-8374.
26. Chesi M., Nardini E., Brents L.A., Schrock E., Ried T., Kuehl W.M., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics 1997, 16:260-264.
27. Pollock P.M., Gartside M.G., Dejeza L.C., Powell M.A., Mallon M.A., Davies H., et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007, 26:7158-7162.
28. Byron S.A., Gartside M.G., Wellens C.L., Mallon M.A., Keenan J.B., Powell M.A., et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Research 2008, 68:6902-6907.
29. Pardo O.E., Latigo J., Jeffery R.E., Nye E., Poulsom R., Spencer-Dene B., et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Research 2009, 69:8645-8651.
30. Zhang J., Zhang L., Su X., Li M., Xie L., Malchers F., et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18:6658-6667.
31. Ware K.E., Marshall M.E., Heasley L.R., Marek L., Hinz T.K., Hercule P., et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PloS ONE 2010, 5:e14117.
32. Terai H., Soejima K., Yasuda H., Nakayama S., Hamamoto J., Arai D., et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC Cells. Molecular Cancer Research: MCR 2013, 11(7):1-9.
33. Berger W., Setinek U., Mohr T., Kindas-Mugge I., Vetterlein M., Dekan G., et al. Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. International Journal of Cancer. Journal International Du Cancer 1999, 83:415-423.
34. Fischer H., Taylor N., Allerstorfer S., Grusch M., Sonvilla G., Holzmann K., et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Molecular Cancer Therapeutics 2008, 7:3408-3419.
35. Ueng T.H., Chang Y.L., Tsai Y.Y., Su J.L., Chan P.K., Shih J.Y., et al. Potential roles of fibroblast growth factor-9 in the benzo(a)pyrene-induced invasion in vitro and the metastasis of human lung adenocarcinoma. Archives of Toxicology 2010, 84:651-660.
36. White A.C., Xu J., Yin Y., Smith C., Schmid G., Ornitz D.M. FGF9 and SHH signaling coordinate lung growth and development through regulation of distinct mesenchymal domains. Development 2006, 133:1507-1517.